Episode 11: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the September issue of the Journal of Thoracic Oncology. Shun Lu, MD, PhD, Associate editor for the Journal of Thoracic Oncology; Director of Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine discusses their article SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China; and Hidetoshi Hayashi, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine discusses their article Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
- SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China G22
-
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
- JTO Volume 21, Issue 9 - September 2026
Hosts
Alex A. Adjei, MD, PhD, FACP
Editor-in-Chief, Journal of Thoracic Oncology
Chief, Taussig Cancer Institute,
Cleveland Clinic, Ohio, United States.
Thomas John, MBBS, PhD
Associate Editor, Journal of Thoracic Oncology
Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre,
Melbourne, Australia.
Guests
Hidetoshi Hayashi, MD, PhD
Professor
Department of Medical Oncology,
Kindai University Faculty of Medicine,
Osaka, Japan
Shun Lu, MD, PhD
Director, Department of Medical Oncology, Shanghai Chest Hospital,
Chief, Shanghai Lung Cancer Center
Shanghai Jiao Tong University School of Medicine
Shanghai, China